Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

NCT03555422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Selinexor
DRUG: Matching placebo for selinexor

Sponsor

Karyopharm Therapeutics Inc

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]